PIK3CA and neoplasm: In conclusion, this study showed that a corresponding circulating PIK3CA mutation was identified in 55% of non-metastatic IBC patients with baseline somatic PIK3CA mutations in tumour tissue and with detectable cfDNA, while no circulating mutation was found among patients with no PIK3CA mutations.